메뉴 건너뛰기




Volumn 635, Issue 1-3, 2010, Pages 165-170

Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist

Author keywords

Anticoagulation; Heparin; PM102; Protamine

Indexed keywords

HEPARIN; HEPARIN ANTAGONIST; HEPARREST; PM 102; PROTAMINE; UNCLASSIFIED DRUG;

EID: 77952323138     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.03.016     Document Type: Article
Times cited : (21)

References (19)
  • 1
    • 77952322021 scopus 로고    scopus 로고
    • A.P.P. Pharmaceuticals, Package Insert, Schaumburg, IL
    • Protamine Sulfate Injection USP 2008, A.P.P. Pharmaceuticals, Package Insert, Schaumburg, IL.
    • (2008) Protamine Sulfate Injection USP
  • 4
    • 77952320856 scopus 로고    scopus 로고
    • Heparin-binding peptides
    • US Patent No. 6,200,955
    • Harris, R.B., Sobel, M., 2001. Heparin-binding peptides. US Patent No. 6,200,955.
    • (2001)
    • Harris, R.B.1    Sobel, M.2
  • 5
    • 0030017370 scopus 로고    scopus 로고
    • Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass
    • Kikura M., Lee M.K., Levy J.H. Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass. Anesth. Analg. 1996, 83:223-227.
    • (1996) Anesth. Analg. , vol.83 , pp. 223-227
    • Kikura, M.1    Lee, M.K.2    Levy, J.H.3
  • 6
    • 0031984680 scopus 로고    scopus 로고
    • Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting
    • Kimmel S.E., Sekeres M.A., Berlin J.A., Goldberg L.R., Strom B.L. Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting. J. Clin. Epidemiol. 1998, 51:1-10.
    • (1998) J. Clin. Epidemiol. , vol.51 , pp. 1-10
    • Kimmel, S.E.1    Sekeres, M.A.2    Berlin, J.A.3    Goldberg, L.R.4    Strom, B.L.5
  • 7
    • 0036261833 scopus 로고    scopus 로고
    • Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass
    • Kimmel S.E., Sekeres M., Berlin J.A., Ellison N. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth. Analg. 2002, 94:1402-1408.
    • (2002) Anesth. Analg. , vol.94 , pp. 1402-1408
    • Kimmel, S.E.1    Sekeres, M.2    Berlin, J.A.3    Ellison, N.4
  • 9
    • 0029044753 scopus 로고
    • Heparin neutralization by recombinant platelet factor 4 and protamine
    • Levy J.H., Cormack J.G., Morales A. Heparin neutralization by recombinant platelet factor 4 and protamine. Anesth. Analg. 1995, 81:35-37.
    • (1995) Anesth. Analg. , vol.81 , pp. 35-37
    • Levy, J.H.1    Cormack, J.G.2    Morales, A.3
  • 11
    • 0042623486 scopus 로고    scopus 로고
    • Dramatic post-cardiotomy outcome, due to severe anaphylactic reaction to protamine
    • Panos A., Orrit X., Chevalley C., Kalangos A. Dramatic post-cardiotomy outcome, due to severe anaphylactic reaction to protamine. Eur. J. Cardiothorac. Surg. 2003, 24:325-327.
    • (2003) Eur. J. Cardiothorac. Surg. , vol.24 , pp. 325-327
    • Panos, A.1    Orrit, X.2    Chevalley, C.3    Kalangos, A.4
  • 12
    • 0026457594 scopus 로고
    • Neutralization of the antithrombotic effects of heparin and Fraxiparin by protamine sulfate
    • Racanelli A., Fareed J. Neutralization of the antithrombotic effects of heparin and Fraxiparin by protamine sulfate. Thromb. Res. 1992, 68:211-222.
    • (1992) Thromb. Res. , vol.68 , pp. 211-222
    • Racanelli, A.1    Fareed, J.2
  • 13
    • 0842264034 scopus 로고    scopus 로고
    • Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo
    • Schick B.P., Maslow D., Moshinski A., San Antonio J.D. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo. Blood 2004, 103:1356-1363.
    • (2004) Blood , vol.103 , pp. 1356-1363
    • Schick, B.P.1    Maslow, D.2    Moshinski, A.3    San Antonio, J.D.4
  • 14
    • 0033378046 scopus 로고    scopus 로고
    • Development of heparin antagonists with focused biological activity
    • Shenoy S., Sobel M., Harris R.B. Development of heparin antagonists with focused biological activity. Curr. Pharm. Des. 1999, 5:965-986.
    • (1999) Curr. Pharm. Des. , vol.5 , pp. 965-986
    • Shenoy, S.1    Sobel, M.2    Harris, R.B.3
  • 16
    • 77952323708 scopus 로고    scopus 로고
    • Peptides for heparin and low molecular weight heparin anticoagulation reversal
    • United States Patent No. 5,534,619
    • Wakefield, T.W., Stanley, J.C., Andrews, P.C., 1996. Peptides for heparin and low molecular weight heparin anticoagulation reversal. United States Patent No. 5,534,619.
    • (1996)
    • Wakefield, T.W.1    Stanley, J.C.2    Andrews, P.C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.